|
| GOLD SPONSORS |
|
|
|
|
|
| SILVER SPONSORS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| OCTOBER 26, 2011, THE METROPOLITAN CLUB, NYC |
|
|
|
|
 |
Lindsay A. Rosenwald
Co-Founder
Opus Point Partners
|
| Dr. Lindsay A. Rosenwald is Co-Founder of Opus Point Partners with Michael Weiss. Opus invests across healthcare, with a focus on biotechnology and life sciences, making open-market purchases as well as direct investments in publicly-traded companies, primarily through its Innovations Fund, launched August, 2008 and its Low Net Fund, launched January, 2009. The firm is located in New York City and currently manages about $70 million in assets. Prior to Opus Point, Dr. Rosenwald was the founder and Chairman of the Paramount Group of Companies, which were focused on the development of promising drugs. One of Dr. Rosenwald’s most recent accomplishments was the sale of his company, Cougar Biotechnology, a firm with a specific focus on prostate cancer, to Johnson & Johnson for about one billion dollars after results from Phase II clinical trials were available. From 1994 to 2007 Dr. Rosenwald was the investment manager of the Aries Funds, long/short alternative investment funds. From 2002 through 2006 he managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs. Dr. Rosenwald received his M.D. from Temple University School of Medicine in 1983 and his B.S. in Finance from Pennsylvania State University in 1977. He maintained a private practice for two years, and in 1986 he moved to Wall Street to develop his career as a physician/analyst. |
|
|
|
